Shares in ElectroCore, Inc. (ECOR) more than doubled after the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of its gammaCore Sapphire device to treat adult patients with COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.The stock surged to $2.20 in Monday’s morning market trading after the U.S. medical device maker announced that the EUA was granted for acute use of the the hand-held device at home or healthcare settings for COVID-19 patients for whom approved drug therapies are not tolerated or provide insufficient symptom relief.The stimulation device is applying …read more
Source:: Yahoo Finance
